During direct compression of a low-dose 2-amino-5-chloropyridine blend on a rotary tablet press, segregation control is governed by the interaction between API particle size distribution and diluent bulk density. A preblend containing 5–20% w/w jet-milled 2-amino-5-chloropyridine, 55–70% w/w microcrystalline cellulose, 15–30% w/w anhydrous lactose, 2–5% w/w croscarmellose sodium, and 0.5–1.5% w/w magnesium stearate is prepared by low-shear tumble blending at 10–15 rpm for 15–25 minutes. The choice of anhydrous lactose over mannitol in this direct compression platform is linked to the brittle fracture behaviour of anhydrous lactose under compaction pressures between 80 MPa and 180 MPa, which produces clean particle fracture surfaces and reduces lamination tendency when the API particles are cohesive. If the API fraction has a bulk density differential greater than 0.3 g/cm³ relative to the filler phase, a 0.5–1.0% w/w colloidal silicon dioxide addition is split between the initial dry mix and the final lubrication step to limit percolation segregation during hopper discharge.

Lubrication is performed separately after the preblend has passed through a 600 µm mesh sieve to break soft agglomerates. The final blend is lubricated with magnesium stearate for an additional 3–5 minutes in a bin blender at 10 rpm; extended lubrication beyond 10 minutes can form a hydrophobic film on filler surfaces and reduce tablet tensile strength by more than 30% in formulations with high microcrystalline cellulose content. Feed frame speed on a 10-station instrumented rotary press is held below 40 rpm because die filling variability increases when the feed shoe paddle speed exceeds the consolidation rate of fine API agglomerates. Tablet weight is monitored by force-displacement profile rather than final hardness alone; capping and lamination defects are detected by the ejection force signature rising above 400 N on individual punches.

Tablets are compressed to a target hardness of 60–100 N and a friability below 1.0% as measured by USP 1217. Disintegration is tested in 900 mL of purified water at 37±2°C per USP 701, with a limit of not more than 15 minutes for uncoated tablets. Content uniformity follows USP 905 with an acceptance value of not more than 15. The final tablet core is suitable for film coating with an aqueous hydroxypropyl methylcellulose-based system at a weight gain of 2–4% w/w; the coating pan inlet air temperature is set at 60–70°C to maintain a product bed temperature of 38–42°C, preventing the API from undergoing solid-state polymorphic conversion during the coating process.

Compliance for this direct compression route rests on ICH Q3D elemental impurity control and FDA 21 CFR 211.110 in-process sampling. A pre-drying step for the API is required if dynamic vapour sorption shows mass gain above 2% w/w at 60% RH within 24 hours; tableting at ambient relative humidity above 60% may otherwise increase sticking and punch filming. The end product is a compacted immediate-release tablet core suitable for film coating, but dissolution performance must be confirmed across USP 711 media at pH 1.2, pH 4.5, and pH 6.8 before release because the solubility of 2-amino-5-chloropyridine is pH-dependent and can shift the dissolution rate in low-pH media if the salt form is not controlled.

What filler-binder ratio prevents segregation in low-dose capsule filling?

Segregation in low-dose capsule filling is controlled less by the absolute API concentration than by the density match between the active fraction and the diluent blend. On a dosator-type capsule filler, a direct fill formulation containing 3–15% w/w 2-amino-5-chloropyridine, 70–85% w/w pregelatinised starch, 10–20% w/w microcrystalline cellulose, 0.5–2.0% w/w sodium stearyl fumarate, and 0–1.0% w/w colloidal silicon dioxide is discharged from a gravity-fed hopper into size 0 or size 1 hard gelatin capsules at fill weights between 250 mg and 400 mg. The pregelatinised starch grade is selected for its tapped density of 0.60–0.70 g/cm³, which bridges the density gap between the active substance and the capsule fill volume requirement without inducing plug formation in the dosator nozzle.

Blending is executed in a tumble bin blender at 10–12 rpm for 20–30 minutes; the API is first passed through a 300 µm screen with an equal portion of pregelatinised starch to deagglomerate fine particles. The homogeneity of the blend is tested at 3 minutes, 10 minutes, and 20 minutes by near-infrared spectroscopy or HPLC assay of top, middle, and bottom thief samples. A blend is considered suitable for capsule filling when the relative standard deviation of the API assay across sampling points remains below 5.0%. If the angle of repose exceeds 40°, the colloidal silicon dioxide level is increased stepwise in 0.25% w/w increments until the flow function coefficient measured by a ring shear tester reaches at least 4.0.

During the encapsulation run, dosator nozzle diameter is set to 6.0–8.0 mm and compression pressure is maintained at 40–80 N to produce a plug with sufficient mechanical integrity for transfer without excessive porosity. In-process weight checks are performed every 15 minutes on 20 capsules, with an individual weight acceptance limit of ±5.0% and a lot mean within ±2.0% of target. Content uniformity follows USP 905, and the dissolution profile is established in USP 711 apparatus II at 50 rpm across the same three media as the tablet route. Hard gelatin capsules are chosen over hypromellose capsules when the fill formulation has a water activity below 0.6, because lower water activity reduces crosslinking of gelatin over long-term storage.

Residual solvent control is governed by ICH Q3C, particularly if the API was isolated from a chlorinated solvent system; the finished capsule must meet ICH Q3C limits for Class 1 and Class 2 residual solvents. Compliance includes 21 CFR 211.80 for incoming excipient identity, 21 CFR 211.110 for in-process blend uniformity, and ICH Q3D for elemental impurities from capsule shell pigments. The terminal product is a hard gelatin capsule filled with a directly compressible or densified powder plug, intended for immediate release but limited by the moisture sensitivity of the capsule shell and the API’s propensity to form static charges during transfer from the dosator to the lower body.

When aqueous wet granulation is selected for 2-amino-5-chloropyridine, the binder addition rate and impeller speed determine granule porosity and tableting index. A high-shear granulator with a main impeller speed of 200–400 rpm and chopper speed of 1500–3000 rpm is charged with 10–25% w/w API, 50–65% w/w lactose monohydrate, 15–25% w/w microcrystalline cellulose, 2–5% w/w crospovidone intragranular, and 2–4% w/w povidone K30 or hypromellose as binder. The binder solution is prepared at 5–10% w/w solids in purified water and added at a rate of 10–30 g/min per kg dry mix. Granulation endpoint is monitored by impeller torque rise and by visual growth under a stereomicroscope; the target granule size distribution is 150–850 µm with a mass median diameter near 300 µm. If the water addition exceeds 8–10% w/w of the dry mix, the granule population shifts to larger than 1000 µm and the subsequent drying time increases by more than 40%.

The wet mass is discharged through a 4 mm square mesh screen and dried in a fluid bed dryer with inlet air temperature 55–70°C, product temperature 30–38°C, and air velocity 1.0–1.5 m/s. Drying is continued until loss on drying is 1.5–2.5% w/w, as determined by a halogen moisture analyser at 105°C. The dried granules are milled through a 1.0 mm screen using an oscillating granulator at 50–80 rpm, and the milled fraction is blended with 2–5% w/w extragranular crospovidone, 0.5–1.5% w/w magnesium stearate, and 0.5–1.0% w/w colloidal silicon dioxide for 5–10 minutes in a V-blender at 10 rpm. The intragranular and extragranular disintegrant split is critical because the intragranular portion creates liquid wicking within the granule, while the extragranular portion drives tablet disintegration after compression.

Tablets are compressed on a rotary press with precompression force 3–6 kN and main compression force 12–25 kN, producing tablet hardness between 70–120 N and friability below 0.8%. The higher compression force range relative to direct compression is possible because wet granulation increases the yield pressure of the granular material and reduces the incidence of lamination. Dissolution is measured in USP 711 apparatus II at 75 rpm to compensate for the stronger tablet matrix; if the release profile differs from the direct compression formulation, the extragranular crospovidone concentration is adjusted in 0.5% w/w steps to match the target release profile. The terminal product is a film-coated tablet core with a weight gain of 2.5–4.0% w/w, and the coating process is performed in a perforated pan with inlet air 60–70°C.

Compliance includes ICH Q3D for elemental impurities introduced by the high-shear granulator contact surfaces, USP 701 for disintegration with a limit of not more than 15 minutes in 900 mL purified water at 37±2°C, and ICH Q3B for degradation products generated during wet massing. If the compound is sensitive to hydrolytic degradation, the binder solvent can be switched to a hydroalcoholic solution of 30% w/w ethanol, but residual ethanol must then comply with ICH Q3C Class 3 limits of not more than 5000 ppm or local pharmacopoeial acceptance criteria. In-process particle size analysis by sieve stack is performed on at least 3 samples per batch to demonstrate a distribution reproducibility standard deviation below 5% across sieve fractions.

Terminal sterilisation constraints for parenteral grade 2-amino-5-chloropyridine solutions

The terminal sterilisation pathway for parenteral solutions of 2-amino-5-chloropyridine is constrained by three variables: pH-dependent hydrolytic degradation, buffer species effect on colour formation, and headspace oxygen content. A standard aqueous vehicle is prepared at 2–10 mg/mL API concentration in a buffer selected from citrate, acetate, or phosphate systems, with pH adjusted to the point of maximum chemical stability and sufficient solubility. Published thermodynamic solubility data for this compound across pharmaceutical buffer systems is limited; a shaking-flask solubility screen at 37±0.5°C for 24 hours per USP 1236 is therefore required before final vehicle selection. Sodium chloride is added to achieve an osmolality of 280–320 mOsm/kg, and the dissolved oxygen is reduced to below 2 mg/L by nitrogen sparging or vacuum-assisted headspace replacement.

The filtered solution must be sterile filtered through a 0.22 µm polyvinylidene fluoride or polyethersulfone membrane, with filter integrity testing performed by bubble point or forward-flow test before and after filtration per 21 CFR 211.167. The filling line is configured for aseptic filling into borosilicate Type I glass vials with siliconised chlorobutyl stoppers; stopper moisture content is verified at or below 0.5% w/w to minimise headspace moisture. If terminal sterilisation by saturated steam at 121°C for 15 minutes is selected, the decision must be supported by an autoclave mapping study showing a minimum F0 value of 15 minutes across the load, and by forced degradation studies showing no more than 0.5% area increase in total impurities under the terminal sterilisation cycle. If the compound degrades beyond that limit, aseptic filtration is the fallback route.

Particulate matter is controlled through USP 787 and USP 790; subvisible particle counts must not exceed 6000 particles per container for particles ≥10 µm and 600 particles per container for particles ≥25 µm. The formulation is filled under unidirectional airflow with an air velocity of 0.36–0.54 m/s in a Grade A zone over a Grade B background. Bacterial endotoxin is controlled by USP 85, with a limit derived from the maximum dose and the route of administration. The finished product is a sterile injectable solution in Type I glass vials with a closure that maintains container closure integrity at a leak rate below 0.1 cm³/min under vacuum decay testing.

Compliance for this route includes ICH Q1A(R2) photostability and thermal cycling studies, 21 CFR 211.94 for container closure system, and ICH Q3B for degradation products. If a pH-adjusting agent such as sodium hydroxide or hydrochloric acid is used, anion and cation limits must be incorporated into the ICH Q3D elemental impurity risk assessment. The operational boundary is defined by the pH stability profile: outside the pH range where the compound shows less than 5% degradation at 25°C over 12 months, the parenteral route is considered non-viable without lyophilisation.

If a lyophilised injectable requires a crystalline bulking agent, the annealing step sets residual moisture limits

Freezing a 2-amino-5-chloropyridine injectable at a shelf ramp rate of 0.5–1.0°C/min produces large ice crystals and a high primary drying resistance in the dried cake. A lyophilisation vehicle containing 5–20 mg/mL API, 3–5% w/v mannitol, 1–2% w/v sucrose or trehalose, and a buffer at 10–25 mM ionic strength is filled at 2–10 mL per vial. The mannitol fraction is selected to provide a crystalline bulk matrix after annealing, while the sucrose or trehalose fraction remains amorphous and serves as a lyoprotectant. The critical formulation parameter is the ratio of amorphous to crystalline excipient; a mannitol fraction above 5% w/v risks incomplete dissolution during freezing, while a sucrose fraction above 3% w/v can lower the collapse temperature below the achievable shelf temperature for primary drying.

Annealing is introduced when the thermal analysis shows incomplete mannitol crystallisation or vial-to-vial freezing heterogeneity. The freezing step is held at −40°C for 2–4 hours, raised to −20°C at 0.1–0.2°C/min for annealing, held for 2–6 hours, and returned to −40°C before primary drying. The primary drying shelf temperature is set at −15°C to −5°C with a chamber pressure of 50–100 mTorr; the product temperature must remain below the glass transition temperature of the maximally freeze-concentrated solute by at least 5°C to avoid collapse. If the collapse temperature falls below −25°C, the ratio of sucrose to mannitol is reduced and the freeze-dry microscopy result is revalidated.

Secondary drying is conducted at 20–30°C under a chamber pressure of 50–80 mTorr for 4–8 hours, targeting a residual moisture content below 1.0% w/w for a crystalline cake or below 3.0% w/w for an amorphous cake as measured by Karl Fischer titration. The final lyophilised cake should be uniform, white to off-white, and free of meltback or shrinkage; cake height loss greater than 10% after tapping indicates insufficient mechanical strength. Reconstitution time is tested with 2 mL of water for injection at 20–25°C, with a target complete dissolution in less than 2 minutes; residual subvisible particulates are then assessed by light obscuration per USP 787.

Compliance for the lyophilised product includes ICH Q3B for degradation products after reconstitution, USP 922 for water activity if a moisture-sensitive cake is released, and 21 CFR 211.166 for stability testing across at least three commercial-scale batches. The operational boundary is the product temperature during primary drying: exceeding the collapse temperature by even 2–3°C produces a collapsed or glassy cake that fails reconstitution and increases residual moisture. Batch-to-batch variability in freeze-dryer shelf contact temperature is controlled by placing calibrated thermocouples in at least 10 vials distributed across the shelf stack and by mapping the condenser capacity before scale-up.

Immediately after fluid bed granulation of a 2-amino-5-chloropyridine sachet formulation, the milled granule fraction is subjected to tapped density and particle size analysis before blending with extragranular disintegrant. The granule fraction is produced by top-spray fluid bed granulation of a dry mix containing 1–10% w/w micronised 2-amino-5-chloropyridine, 60–80% w/w mannitol, 5–15% w/w low-substituted hydroxypropyl cellulose, and 2–5% w/w sodium starch glycollate. A binder solution of povidone K30 at 5% w/w solids is sprayed at a rate of 5–15 g/min per kg dry mix using a 1.0 mm two-fluid nozzle with atomisation air pressure 1.5–2.5 bar. Inlet air temperature is controlled at 60–70°C, product temperature at 30–35°C, and relative humidity of the exhaust air below 40% to prevent overwetting. The granulation endpoint is reached when the product moisture by loss on drying is 1.5–2.5% w/w and the mass median granule diameter is 250–500 µm as measured by sieve analysis.

After cooling to 25°C, the dried granules are milled through a 0.8–1.2 mm screen and blended with 1–2% w/w colloidal silicon dioxide, 0.5–1.5% w/w sodium stearyl fumarate, and, if required, a flavour and sweetener system in a twin-shell blender at 10 rpm for 10–15 minutes. The final blend is filled into sachets at a fill weight of 1.0–5.0 g using a vertical form-fill-seal machine with servo-driven auger dosing. Fill weight accuracy is maintained at ±3% of target by in-line checkweighing, and seal integrity is tested by vacuum decay with a leak limit of 0.05 L/min under −200 mbar.

The sachet material is selected as a triplex laminate of polyethylene terephthalate, aluminium foil, and linear low-density polyethylene with a total thickness of 90–120 µm; the aluminium foil layer provides water vapour transmission below 0.3 g/m²/24 h at 38°C and 90% RH. If the API is moisture-sensitive, a desiccant sachet is not used inside because of the risk of direct contact with the granules; instead, the primary sachet itself serves as the moisture barrier. Dissolution of the reconstituted granules is tested in USP 711 apparatus II with 900 mL of purified water at 37±2°C after dispersing the sachet contents, with a target release of not less than 75% at 30 minutes.

Compliance for this granule route includes ICH Q3B for degradation products, Ph Eur 2.9.12 for sieve retention, and 21 CFR 211.68 for in-line checkweighing and metal detection. The terminal product is a moisture-protected oral granule sachet that requires reconstitution or can be swallowed directly after dispersion in water; the operational boundary is the fluid bed granulation overwetting point, beyond which the granule fraction above 850 µm exceeds 30% w/w and the final blend segregates during sachet filling. Routine batch release also includes bulk and tapped density ratio below 1.25 as an indicator of flowability through the auger dosing system.